Pfizer says 3 COVID shots protect children under 5 Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week The Independent UK · May 23, 2022
Omicron infection turbo-charges vaccinated people’s immunity: study People who are vaccinated and then get infected with Omicron may be primed to overcome a broad range of coronavirus variants, early research suggests. Bangkok Post · May 15, 2022
Where BioNTech Stands With Analysts Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings: Benzinga · May 10, 2022
Why BioNTech Stock Is Rising Today BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook. Benzinga · May 9, 2022
BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine. In Q1 FY22, BioNTech and its partner Pfizer Inc (NYSE:PFE) have invoiced approximately 750 million COVID-19 vaccine doses. As of end-April 2022, the companies have signed orders… Benzinga · May 9, 2022
How To Attend BioNTech Q1 2022 Earnings Conference Call BioNTech (NASDAQ:BNTX) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend BioNTech (BNTX) Conference Call Follow this link to access the live webcast. Benzinga · May 4, 2022
Pfizer accused of Covid profiteering as first-quarter sales hit $26bn Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill The Guardian - UK · May 3, 2022
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis Here's a roundup of top developments in the biotech space over the last 24 hours. Benzinga · Apr 27, 2022
Another delay for five-and-under vaccine The issue isn't around safety, but instead messaging and vaccine effectiveness Salon · Apr 26, 2022
What's Happening With BioNTech SE Shares? Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China. Benzinga · Apr 25, 2022
If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom. Benzinga · Apr 22, 2022
Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years. Benzinga · Apr 14, 2022
Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11 A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday. Reuters · Apr 14, 2022
HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar Benzinga · Apr 12, 2022
Benzinga · Apr 12, 2022 Expert Ratings for BioNTech Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:
Benzinga · Apr 11, 2022 Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have
Benzinga · Apr 11, 2022 Here's Why Matinas BioPharma Shares Are Rising Matinas BioPharma Holdings Inc (NASDAQ: MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines.
The Independent UK · Apr 6, 2022 Sadiq Khan calls on leading vaccine manufacturers to share Covid jab blueprints with world Exclusive: Sadiq Khan, alongside mayors of New York and Johannesburg, urged companies ‘to do all you can’ to promote vaccine equity and ‘help stop the unnecessary loss of life’
Benzinga · Apr 5, 2022 mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha
Reuters · Mar 31, 2022 Governments want COVID vaccine developers to aim higher in hunt for better shots As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.
Benzinga · Mar 30, 2022 BioNTech Whale Trades Spotted Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · Mar 30, 2022 Why BioNTech Shares Are Surging Today BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…
Benzinga · Mar 30, 2022 Recap: BioNTech Q4 Earnings BioNTech (NASDAQ:BNTX) reported its Q4 earnings results on Wednesday, March 30, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
The Independent UK · Mar 30, 2022 BioNTech's quarterly profit soars on COVID-19 vaccine demand BioNTech has reported another quarter of strong earnings growth
Benzinga · Mar 29, 2022 Earnings Outlook For BioNTech BioNTech (NASDAQ:BNTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will report an earnings per share (EPS) of $8.19.